Metrics as of 10/17/2026, 08:50 AM (Berlin time), refresh in progress.
Arcus Biosciences Stock
Arcus Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Terry J. Rosen
- Employees
- 601
- Market cap
- $2.8 B
- IPO
- 14/03/2018
- Web
- arcusbio.com
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California. Founded in 2015, the company develops and commercializes cancer therapies within the United States. The development product portfolio includes Casdatifan, a HIF-2a inhibitor for treating kidney cancer, and Domvanalimab,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Arcus Biosciences stock: price history
1D
-3.1%
1W
-9.4%
1M
-10.3%
6M
-8.8%
YTD
-7.2%
1Y
+33.3%
2Y
+23.9%
5Y
-35.7%
10Y
–
Next earnings date
Next earnings date
27/10/2026 (in 10 days)
Volatility around earnings
~20% stronger price swings than usual
Ask the agents about Arcus Biosciences
Analyst assessment of Arcus Biosciences
PRICE TARGET LOW
US$23.00
CONSENSUS
US$40.00
MEDIAN
US$42.50
PRICE TARGET HIGH
US$47.00
0
STRONG BUY
15
BUY
3
HOLD
0
SELL
0
STRONG SELL
18
TOTAL · Buy
As of: 30/09/2026
Arcus Biosciences stock metrics
P/E
-5.63
P/B
6.01
EV/EBITDA
-6.55
RETURN ON EQUITY
-19.6%
NET MARGIN
-222.0%
DEBT/EQUITY
0.25
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
72.0%
FLOAT SHARES
90,526,390
AVG. DAILY VOLUME (30D)
1,619,600
Insider transactions (SEC)
Azoy Alexander
Azoy Alexander
Jaen Juan C.
Jaen Juan C.
Jaen Juan C.
Institutional holders
Comparable stocks
Frequently asked questions about Arcus Biosciences stock
What does Arcus Biosciences do?
Arcus Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Terry J. Rosen, the company employs around 601 people.
The IPO was on 14/03/2018; the stock trades on NYSE under the ticker RCUS.
What do analysts say about Arcus Biosciences stock?
18 analysts rate the stock, the consensus is Buy (as of 30/09/2026).
The average price target is US$40.00, ranging from US$23.00 to US$47.00, with a median of US$42.50.
This is an external assessment, not a statement by Market Jury.
When does Arcus Biosciences report next?
The next earnings date is 27/10/2026.
Around past earnings, price swings were roughly 20% stronger than usual.
Does Arcus Biosciences pay a dividend?
No, Arcus Biosciences currently does not pay a dividend.
Which stocks are comparable to Arcus Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Arcus Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Arcus Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.